Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Halozyme Therapeutics Stock Down 0.4 %

Shares of Halozyme Therapeutics stock opened at $57.70 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The stock has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.82, a P/E/G ratio of 0.42 and a beta of 1.25. The company’s 50 day moving average price is $54.08 and its 200-day moving average price is $54.71.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HALO shares. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Private Advisor Group LLC boosted its holdings in Halozyme Therapeutics by 6.2% in the third quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock valued at $1,383,000 after acquiring an additional 1,410 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Halozyme Therapeutics by 5,623.9% in the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company’s stock valued at $20,940,000 after acquiring an additional 35,937 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Halozyme Therapeutics by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 782 shares in the last quarter. State of Alaska Department of Revenue lifted its position in Halozyme Therapeutics by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 995 shares during the period. Finally, Nisa Investment Advisors LLC lifted its position in Halozyme Therapeutics by 32.8% during the third quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 1,358 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.